These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26866496)

  • 21. Botulinum toxin treatment of axial and cervical dystonia.
    Benecke R; Dressler D
    Disabil Rehabil; 2007 Dec; 29(23):1769-77. PubMed ID: 18033602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F.
    Eleopra R; Tugnoli V; Quatrale R; Rossetto O; Montecucco C; Dressler D
    Neurotox Res; 2006 Apr; 9(2-3):127-31. PubMed ID: 16785109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A.
    Houser MK; Sheean GL; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):577-80. PubMed ID: 9598669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
    Comella CL; Jankovic J; Truong DD; Hanschmann A; Grafe S;
    J Neurol Sci; 2011 Sep; 308(1-2):103-9. PubMed ID: 21764407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
    Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
    Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-traumatic cervical C1-C2 subluxation.
    Lefaucheur R; Derrey S; Fetter D; Wallon D; Gilard V; Maltête D
    Joint Bone Spine; 2014 Dec; 81(6):545-6. PubMed ID: 24703623
    [No Abstract]   [Full Text] [Related]  

  • 27. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.
    Atassi MZ; Jankovic J; Steward LE; Aoki KR; Dolimbek BZ
    Immunobiology; 2012 Jan; 217(1):17-27. PubMed ID: 21962573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Use of Botulinum Toxin in the Management of Headache Disorders.
    Silberstein SD
    Semin Neurol; 2016 Feb; 36(1):92-8. PubMed ID: 26866501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of cervical dystonia (torticollis) in adults with botulinum A toxin.
    Metzer WS; Jenkins T
    J Ark Med Soc; 1992 Aug; 89(3):133-4. PubMed ID: 1517180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Botulinum toxin A for the treatment of cervical dystonia.
    Zesiewicz TA; Stamey W; Sullivan KL; Hauser RA
    Expert Opin Pharmacother; 2004 Sep; 5(9):2017-24. PubMed ID: 15330738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Botulinum toxin type B: where do we stand?
    Dressler D
    Eur Neurol; 2001; 46(3):113-4. PubMed ID: 11598327
    [No Abstract]   [Full Text] [Related]  

  • 32. Management of Anterocapitis and Anterocollis: A Novel Ultrasound Guided Approach Combined with Electromyography for Botulinum Toxin Injection of Longus Colli and Longus Capitis.
    Farrell M; Karp BI; Kassavetis P; Berrigan W; Yonter S; Ehrlich D; Alter KE
    Toxins (Basel); 2020 Sep; 12(10):. PubMed ID: 33008043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes.
    Hubble J; Schwab J; Hubert C; Abbott CC
    Clin Neuropharmacol; 2013; 36(4):122-7. PubMed ID: 23783005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical Dystonia.
    Tilden D; Guarnieri C
    Value Health; 2016; 19(2):145-52. PubMed ID: 27021747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on the Use of Botulinum Toxin Therapy for Focal and Task-Specific Dystonias.
    Lungu C; Ahmad OF
    Semin Neurol; 2016 Feb; 36(1):41-6. PubMed ID: 26866495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia.
    Benecke R; Jost WH; Kanovsky P; Ruzicka E; Comes G; Grafe S
    Neurology; 2005 Jun; 64(11):1949-51. PubMed ID: 15955951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sonographic Guide for Botulinum Toxin Injections of the Neck Muscles in Cervical Dystonia.
    Kaymak B; Kara M; Gürçay E; Özçakar L
    Phys Med Rehabil Clin N Am; 2018 Feb; 29(1):105-123. PubMed ID: 29173657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cervical dystonia treatment with botulin toxin].
    Tomczykiewicz K
    Pol Merkur Lekarski; 2016 Aug; 41(242):107-10. PubMed ID: 27591450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B.
    Oshima M; Deitiker PR; Jankovic J; Duane DD; Aoki KR; Atassi MZ
    J Neuroimmunol; 2011 Dec; 240-241():121-8. PubMed ID: 22079193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Botulinum toxin therapy for focal dystonia].
    Hahn K; Niklai E; Garzuly F; Szupera Z
    Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.